Physician profile
Lin Lwin
NPI 1053407031
$1,821.45
in general payments reported to CMS, 2019-2025
12 companies · $79.90 in 2025
The $79.90 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $320 · 2021: $249 · 2022: $487 · 2023: $350 · 2024: $119 · 2025: $79.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,136.62 | 2019-2025 | Farxiga |
| Aurinia Pharma U.S., INC. | $206.77 | 2022-2025 | Lupkynis |
| Vifor Pharma, INC. | $125.00 | 2022 | |
| Medtronic Vascular, INC. | $92.41 | 2019 | |
| Akebia Therapeutics INC | $72.49 | 2021-2022 | |
| Ardelyx, INC. | $34.38 | 2024 | Ibsrela |
| Travere Therapeutics, INC. | $32.44 | 2024 | |
| Scpharmaceuticals INC. | $31.31 | 2025 | |
| Amgen INC. | $27.74 | 2023 | Parsabiv, Tavneos |
| Kyowa Kirin, INC. | $27.25 | 2023 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $20.09 | 2022 | |
| Angiodynamics, INC. | $14.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Lwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.